patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_840444 | REC_0001201 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 13.6 | 81 | male | 2 | 11 | 3.5 | 5 | alectinib 600 mg BID | 7 | false | MSS | 2026-03-15T05:35:57.138446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107170 | REC_0001202 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 12.6 | 69 | female | 0 | 6 | 4.6 | 2 | sotorasib 960 mg daily | 18.8 | false | MSS | 2026-03-15T05:35:57.138686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967498 | REC_0001203 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 6.9 | 72 | female | 2 | 15 | 8.3 | 5 | alectinib 600 mg BID | 16 | false | MSS | 2026-03-15T05:35:57.138931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969372 | REC_0001204 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.2 | 52 | male | 0 | 51 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.7 | true | MSS | 2026-03-15T05:35:57.139186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834233 | REC_0001205 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 36 | 16.7 | 75 | female | 2 | 6 | 5.7 | 7 | entrectinib 600 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:57.139439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410217 | REC_0001206 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.2 | 67 | male | 0 | 46 | 4.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.9 | true | MSS | 2026-03-15T05:35:57.139699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544579 | REC_0001207 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 14.3 | 62 | female | 1 | 17 | 6 | 1 | osimertinib 80 mg daily | 20.7 | false | MSI-H | 2026-03-15T05:35:57.139943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499842 | REC_0001208 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 10.5 | 61 | male | 0 | 27 | 7 | 0 | osimertinib 80 mg daily | 43.3 | true | MSS | 2026-03-15T05:35:57.140253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530391 | REC_0001209 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 11.6 | 77 | female | 0 | 12 | 6.4 | 2 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:57.140499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180049 | REC_0001210 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.3 | 75 | female | 2 | 14 | 6.7 | 7 | alectinib 600 mg BID | 14.5 | true | MSS | 2026-03-15T05:35:57.140851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786485 | REC_0001211 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 8.2 | 76 | male | 1 | 15 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.5 | true | MSS | 2026-03-15T05:35:57.141097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166100 | REC_0001212 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 14.4 | 63 | female | 1 | 12 | 4.9 | 8 | entrectinib 600 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:35:57.141340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412204 | REC_0001213 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.9 | 67 | female | 1 | 11 | 5.3 | 7 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.141576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210274 | REC_0001214 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 4.9 | 54 | female | 0 | 23 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.4 | true | MSS | 2026-03-15T05:35:57.141806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707446 | REC_0001215 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.5 | 70 | male | 1 | 4 | 7.3 | 6 | sotorasib 960 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:57.142043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826462 | REC_0001216 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 8.8 | 69 | female | 1 | 15 | 4.1 | 4 | sotorasib 960 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:57.142274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690283 | REC_0001217 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 8.3 | 75 | male | 0 | 8 | 6 | 3 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:35:57.142504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493344 | REC_0001218 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 16.4 | 72 | female | 1 | 9 | 5.8 | 1 | osimertinib 80 mg daily | 21.4 | false | MSS | 2026-03-15T05:35:57.142737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555560 | REC_0001219 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8.4 | 65 | female | 1 | 7 | 4.2 | 5 | sotorasib 960 mg daily | 8.8 | true | MSS | 2026-03-15T05:35:57.142980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139902 | REC_0001220 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 16.9 | 59 | male | 0 | 10 | 5.7 | 1 | entrectinib 600 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.143220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104734 | REC_0001221 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 12.6 | 70 | female | 1 | 18 | 6.5 | 7 | alectinib 600 mg BID | 7.1 | true | MSS | 2026-03-15T05:35:57.143451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342776 | REC_0001222 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.3 | 67 | male | 1 | 13 | 6.5 | 7 | sotorasib 960 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:57.143686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460037 | REC_0001223 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 15.3 | 64 | female | 0 | 22 | 6.5 | 1 | osimertinib 80 mg daily | 22.7 | true | MSI-H | 2026-03-15T05:35:57.143979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417407 | REC_0001224 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.7 | 71 | female | 2 | 10 | 5.8 | 4 | sotorasib 960 mg daily | 8 | false | MSI-H | 2026-03-15T05:35:57.144322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965535 | REC_0001225 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 5.9 | 55 | male | 1 | 23 | 4.9 | 6 | sotorasib 960 mg daily | 5.3 | true | MSS | 2026-03-15T05:35:57.144564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321905 | REC_0001226 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.2 | 60 | female | 1 | 36 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.8 | true | MSS | 2026-03-15T05:35:57.144797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811633 | REC_0001227 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 8.6 | 59 | male | 0 | 23 | 5.7 | 5 | sotorasib 960 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:57.145032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912901 | REC_0001228 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 14 | 9.9 | 67 | female | 1 | 50 | 5.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.7 | true | MSS | 2026-03-15T05:35:57.145262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236316 | REC_0001229 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.9 | 74 | male | 2 | 15 | 5.4 | 3 | alectinib 600 mg BID | 13.2 | true | MSS | 2026-03-15T05:35:57.145500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174158 | REC_0001230 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 12.2 | 89 | female | 1 | 19 | 5.7 | 5 | sotorasib 960 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:57.145735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356385 | REC_0001231 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 19.6 | 69 | female | 1 | 11 | 4.8 | 1 | alectinib 600 mg BID | 11.2 | false | MSS | 2026-03-15T05:35:57.145969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806269 | REC_0001232 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 12.5 | 82 | female | 1 | 18 | 6.1 | 6 | sotorasib 960 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:57.146202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877479 | REC_0001233 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.7 | 64 | male | 1 | 20 | 4.2 | 4 | alectinib 600 mg BID | 13.6 | false | MSI-H | 2026-03-15T05:35:57.146436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415696 | REC_0001234 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.9 | 60 | male | 0 | 11 | 2.9 | 5 | alectinib 600 mg BID | 8.2 | true | MSS | 2026-03-15T05:35:57.146666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651668 | REC_0001235 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.3 | 55 | female | 0 | 70 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.2 | true | MSS | 2026-03-15T05:35:57.146897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524911 | REC_0001236 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 10.2 | 64 | male | 0 | 27 | 4.6 | 2 | osimertinib 80 mg daily | 15 | true | MSI-H | 2026-03-15T05:35:57.147187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613585 | REC_0001237 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 15.4 | 58 | male | 1 | 26 | 5.3 | 1 | osimertinib 80 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:57.147428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286159 | REC_0001238 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.9 | 80 | male | 2 | 41 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:35:57.147661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341829 | REC_0001239 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 20 | 10.4 | 57 | female | 1 | 23 | 5.7 | 0 | alectinib 600 mg BID | 19.3 | false | MSI-H | 2026-03-15T05:35:57.147897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428138 | REC_0001240 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.2 | 65 | male | 0 | 31 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.7 | false | MSS | 2026-03-15T05:35:57.148187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930223 | REC_0001241 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.5 | 63 | male | 1 | 11 | 5.6 | 1 | osimertinib 80 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:35:57.148432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314293 | REC_0001242 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 9.9 | 53 | male | 0 | 8 | 6.3 | 1 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:57.148665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187532 | REC_0001243 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 12.6 | 72 | male | 2 | 5 | 5.9 | 5 | pembrolizumab 200 mg q3w | 7.2 | true | MSS | 2026-03-15T05:35:57.148902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817138 | REC_0001244 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 20.4 | 71 | male | 2 | 15 | 6.1 | 1 | osimertinib 80 mg daily | 23.4 | true | MSS | 2026-03-15T05:35:57.149143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786863 | REC_0001245 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 4.8 | 50 | female | 0 | 8 | 4 | 2 | pembrolizumab 200 mg q3w | 15.8 | true | MSS | 2026-03-15T05:35:57.149376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747559 | REC_0001246 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.4 | 57 | female | 0 | 73 | 7.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.5 | true | MSS | 2026-03-15T05:35:57.149607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196742 | REC_0001247 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 11.6 | 75 | female | 1 | 11 | 6.1 | 1 | osimertinib 80 mg daily | 24.6 | true | MSI-H | 2026-03-15T05:35:57.149840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846418 | REC_0001248 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 13.4 | 52 | male | 0 | 16 | 8.2 | 8 | entrectinib 600 mg daily | 15.3 | true | MSS | 2026-03-15T05:35:57.150074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452676 | REC_0001249 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 9.1 | 77 | female | 1 | 17 | 5.1 | 2 | sotorasib 960 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:57.150349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383033 | REC_0001250 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.4 | 70 | male | 2 | 22 | 5.1 | 5 | sotorasib 960 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:57.150588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687963 | REC_0001251 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 20.9 | 60 | female | 1 | 13 | 6 | 6 | osimertinib 80 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:57.150825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170635 | REC_0001252 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 8.4 | 55 | female | 0 | 56 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:35:57.151056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715098 | REC_0001253 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13 | 68 | female | 1 | 25 | 4.1 | 5 | osimertinib 80 mg daily | 10.6 | false | MSI-H | 2026-03-15T05:35:57.151291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999245 | REC_0001254 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 10.5 | 69 | female | 0 | 25 | 5.8 | 3 | entrectinib 600 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:57.151526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759486 | REC_0001255 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.1 | 67 | female | 1 | 16 | 4.4 | 6 | alectinib 600 mg BID | 8 | true | MSI-H | 2026-03-15T05:35:57.151759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437280 | REC_0001256 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16.9 | 65 | female | 1 | 18 | 5.8 | 5 | osimertinib 80 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:35:57.151992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777019 | REC_0001257 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6.2 | 62 | female | 0 | 46 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.9 | false | MSS | 2026-03-15T05:35:57.152295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279490 | REC_0001258 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.4 | 80 | female | 2 | 12 | 4.9 | 5 | entrectinib 600 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:57.152539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402833 | REC_0001259 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 17 | 66 | female | 1 | 16 | 5.5 | 6 | alectinib 600 mg BID | 11.6 | false | MSI-H | 2026-03-15T05:35:57.152781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910198 | REC_0001260 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 18.1 | 61 | male | 1 | 15 | 5.5 | 6 | osimertinib 80 mg daily | 10.8 | true | MSI-H | 2026-03-15T05:35:57.153016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940919 | REC_0001261 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.8 | 77 | female | 1 | 12 | 2.6 | 2 | sotorasib 960 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:35:57.153250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352209 | REC_0001262 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.1 | 62 | female | 1 | 7 | 6.1 | 6 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:57.153543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889656 | REC_0001263 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 13.2 | 71 | female | 2 | 20 | 3.9 | 3 | osimertinib 80 mg daily | 18.2 | true | MSI-H | 2026-03-15T05:35:57.153784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428589 | REC_0001264 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10.3 | 82 | male | 1 | 16 | 5.8 | 6 | alectinib 600 mg BID | 14.6 | true | MSS | 2026-03-15T05:35:57.154020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726492 | REC_0001265 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 17.2 | 81 | male | 0 | 16 | 5.9 | 6 | sotorasib 960 mg daily | 13.5 | true | MSS | 2026-03-15T05:35:57.154255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561681 | REC_0001266 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 35 | 7.3 | 68 | female | 1 | 14 | 6.5 | 2 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:57.154486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457190 | REC_0001267 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 8.2 | 75 | female | 1 | 28 | 4.4 | 5 | sotorasib 960 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:57.154735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973604 | REC_0001268 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 30 | 7.2 | 63 | male | 0 | 45 | 5.3 | 0 | pembrolizumab 200 mg q3w | 34.2 | true | MSS | 2026-03-15T05:35:57.154985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877202 | REC_0001269 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 6.4 | 73 | female | 1 | 31 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.7 | true | MSS | 2026-03-15T05:35:57.155227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410753 | REC_0001270 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.8 | 65 | male | 1 | 15 | 5.8 | 5 | osimertinib 80 mg daily | 15.2 | true | MSS | 2026-03-15T05:35:57.155481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919047 | REC_0001271 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 4.4 | 56 | male | 0 | 16 | 3.4 | 2 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:57.155730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682151 | REC_0001272 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 5.4 | 75 | female | 1 | 19 | 5.6 | 7 | entrectinib 600 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:57.155960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161816 | REC_0001273 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 14.5 | 67 | female | 0 | 18 | 5.7 | 2 | alectinib 600 mg BID | 12.7 | true | MSI-H | 2026-03-15T05:35:57.156278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302311 | REC_0001274 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 3.4 | 71 | female | 2 | 46 | 4.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.5 | true | MSS | 2026-03-15T05:35:57.156558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222419 | REC_0001275 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 14.8 | 74 | female | 1 | 18 | 5.5 | 1 | osimertinib 80 mg daily | 20.8 | false | MSS | 2026-03-15T05:35:57.156966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858724 | REC_0001276 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.1 | 60 | female | 0 | 9 | 4.5 | 5 | alectinib 600 mg BID | 13.4 | true | MSI-H | 2026-03-15T05:35:57.157290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368273 | REC_0001277 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 6.9 | 63 | female | 1 | 22 | 5.7 | 4 | entrectinib 600 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:57.157583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494696 | REC_0001278 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 29 | 10.6 | 68 | male | 0 | 15 | 4.3 | 0 | osimertinib 80 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:57.157848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318523 | REC_0001279 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 11 | 66 | female | 1 | 23 | 3.9 | 1 | entrectinib 600 mg daily | 24.9 | false | MSI-H | 2026-03-15T05:35:57.158099+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515265 | REC_0001280 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 4.3 | 73 | female | 3 | 30 | 2.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.2 | true | MSS | 2026-03-15T05:35:57.158335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877925 | REC_0001281 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 10.2 | 61 | female | 1 | 16 | 4.6 | 7 | alectinib 600 mg BID | 15.1 | false | MSI-H | 2026-03-15T05:35:57.158574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609639 | REC_0001282 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.7 | 73 | female | 1 | 29 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 20 | false | MSS | 2026-03-15T05:35:57.158817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155222 | REC_0001283 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.5 | 77 | female | 2 | 10 | 5.8 | 2 | osimertinib 80 mg daily | 18 | true | MSS | 2026-03-15T05:35:57.159065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915833 | REC_0001284 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.4 | 74 | female | 2 | 22 | 4.3 | 8 | alectinib 600 mg BID | 13.1 | false | MSI-H | 2026-03-15T05:35:57.159326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758967 | REC_0001285 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13.2 | 76 | male | 2 | 10 | 7.2 | 7 | entrectinib 600 mg daily | 17.7 | true | MSI-H | 2026-03-15T05:35:57.159589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410945 | REC_0001286 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.6 | 76 | female | 3 | 15 | 4.4 | 4 | entrectinib 600 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:57.159842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978534 | REC_0001287 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.2 | 46 | female | 0 | 13 | 7.4 | 4 | sotorasib 960 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:35:57.160151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480099 | REC_0001288 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 13.9 | 64 | male | 0 | 11 | 4.8 | 2 | osimertinib 80 mg daily | 31.9 | true | MSI-H | 2026-03-15T05:35:57.160564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459849 | REC_0001289 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.1 | 69 | female | 1 | 75 | 6.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.4 | false | MSS | 2026-03-15T05:35:57.160817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226040 | REC_0001290 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 9.8 | 78 | male | 2 | 10 | 5.4 | 8 | alectinib 600 mg BID | 7.6 | false | MSS | 2026-03-15T05:35:57.161053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783551 | REC_0001291 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.2 | 76 | female | 1 | 13 | 4.9 | 7 | entrectinib 600 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:57.161296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217564 | REC_0001292 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.9 | 57 | female | 1 | 21 | 5.3 | 6 | entrectinib 600 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:57.161539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112097 | REC_0001293 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 5 | 59 | male | 0 | 10 | 6 | 6 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:57.161772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361101 | REC_0001294 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 16.3 | 78 | female | 1 | 16 | 6.7 | 4 | alectinib 600 mg BID | 10.6 | false | MSS | 2026-03-15T05:35:57.162003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644063 | REC_0001295 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 5.6 | 71 | male | 1 | 20 | 2.8 | 8 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:57.162239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132811 | REC_0001296 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 17.3 | 68 | female | 0 | 16 | 7.6 | 1 | sotorasib 960 mg daily | 24.5 | true | MSS | 2026-03-15T05:35:57.162470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309855 | REC_0001297 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 11.5 | 59 | female | 0 | 6 | 6.4 | 1 | entrectinib 600 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:57.162709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468491 | REC_0001298 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 7.5 | 69 | male | 1 | 8 | 6.1 | 5 | osimertinib 80 mg daily | 14.2 | false | MSS | 2026-03-15T05:35:57.162941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390960 | REC_0001299 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.2 | 59 | female | 1 | 23 | 6.1 | 4 | alectinib 600 mg BID | 10.7 | true | MSS | 2026-03-15T05:35:57.163175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427058 | REC_0001300 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 13.9 | 59 | female | 1 | 21 | 5.5 | 8 | alectinib 600 mg BID | 14.8 | false | MSS | 2026-03-15T05:35:57.163409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.